4 Einträge gefunden

1. Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT-HER2+/HR- trial

   1. Graeser, Monika
   2. Gluz, Oleg
   3. Biehl, Claudia
   4. Ulbrich-Gebauer, Daniel
   5. Christgen, Matthias
   6. Palatty, Jenci
   7. Kuemmel, Sherko

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer

   1. Grote, Isabel
   2. Bartels, Stephan
   3. Christgen, Henriette
   4. Radner, Martin
   5. Gronewold, Malte
   6. Kandt, Leonie
   7. Raap, Mieke

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

   1. Nitz, Ulrike
   2. Gluz, Oleg
   3. Graeser, Monika
   4. Christgen, Matthias
   5. Kuemmel, Sherko
   6. Grischke, Eva-Maria
   7. Braun, Michael

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
4. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

   1. Graeser, Monika
   2. Feuerhake, Friedrich
   3. Gluz, Oleg
   4. Volk, Valery
   5. Hauptmann, Michael
   6. Jozwiak, Katarzyna
   7. Christgen, Matthias

   2021 - Forschungsinformationssystem des UKE - frei zugänglich